Is Edge-to-Edge Treatment with PASCAL Effective at 3 Years?

Mitral regurgitation is the most common valvular heart disease. Its cause is most frequently functional or secondary dysfunction (functional mitral regurgitation, FMR) compared with degenerative mitral regurgitation (DMR), which is associated with decreased ventricular function, hospitalization for heart failure, and mortality.

¿Es efectivo el tratamiento borde a borde con PASCAL a 3 años?

While medical treatment is effective over extended periods, a significant number of patients cannot undergo surgery due to high or extreme surgical risk.

Edge-to-edge treatment has emerged as a valid alternative with promising results compared to comprehensive medical treatment, as shown in the COAPT Study. However, until now, only this analysis and other smaller studies are available, especially regarding long-term outcomes.

The CLASP Study included 124 patients with symptomatic severe mitral regurgitation, of whom 85 had FMR and 39 had DMR.

Major adverse events (MAEs) were assessed at 3 years. MAEs were defined as the presence of cardiovascular mortality, stroke, acute myocardial infarction, need for dialysis, severe bleeding, and device-related reintervention.

Read also: Relationship between Distal Vessel Quality and Outcomes in the Treatment of Chronic Total Occlusions.

Mean age was 75 years, and 55% of subjects were male. About 83% of patients had hypertension, 36% had diabetes, 12% had suffered a prior stroke, 63% had atrial fibrillation, 30% had impaired renal function, 24% had pulmonary hypertension, 35% had moderate to severe tricuspid insufficiency, and NT BNP levels were 4,148 pg/mL.

At 3 years, the MAEs rate was 26.6% (30.6% for FMR and 17.9% for DMR); for cardiovascular mortality, it was 14.5% (18.8% for FMR and 5.1% for DMR). About 4.0% of patients had experienced a stroke (4.7% for FMR and 2.6% for DMR), 3.2% had experienced an acute myocardial infarction (2.4% for FMR and 5.1% for DMR), and 2 patients had required reintervention.

The 3-year survival rate was 74.6% (66.0% for FMR and 91.7% for DMR), and the rate for freedom from rehospitalization for heart failure was 73.1% (63.9% for FMR and 91.1% for DMR).

Read also: Cerebrovascular Events in the COAPT Study.

The annualized hospitalization rate at 3 years decreased by 85%, from 1.17 before the procedure to 0.18 (81% for FMR and 96% for DMR; in both types of mitral regurgitation, p <0.001), and there was a significant improvement in functional class. Additionally, there was a significant reduction in ventricular volume and mitral regurgitation at 30 days, which was maintained at 3 years for both DMR and FMR.

Conclusion

The 3-year results of the CLASP Study demonstrate the durability and favorable evolution of the PASCAL System in symptomatic patients with severe mitral regurgitation. These results further support the use of the PASCAL System as a valuable therapy for patients with symptomatic mitral regurgitation.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Three‐year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study.

Reference: Konstantinos Spargias, et al. Catheter Cardiovasc Interv. 2023;102:145–154.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...